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Background
Methotrexate (MTX) is one of the most common dis-
ease modifying antirheumatic drugs used for the treat-
ment of juvenile idiopathic arthritis (JIA). Reliable
predictors for the efficacy of MTX therapy would be
very helpful for the development of more personalized
therapy in an early stage of the disease.
Aim
We investigated whether Reduced Folate Carrier (RFC)
(C347G), and Aminoimidazole Carboxamide Ribonu-
cleotide Transformylase (ATIC) (G80A) gene poly-
morphisms were related to the efficacy of methotrexate
in JIA patients with a polyarticular course.
Methods
Ninety seven JIA patients with a polyarticular course
were enrolled into the study. All patients received meth-
otrexate treatment for at least for 6 months. The effi-
cacy of treatment was judged by improvement in
physician’s global assesment, the number of affected
joints, erythrocyte sedimentation rate and C-reactive
protein. RFC and ATIC gene polymorphisms were
determined by polymerase chain reaction- restriction
fragment length polymorphism ( PCR-RFLP) analysis.
Results
The median age of the patients was 72 (12-92) months.
The response rate to MTX was 45%. There was no sig-
nificant association between RFC and ATIC polymorph-
isms and efficacy of MTX treatment (p: 0.254, p: 0.098
respectively).
Conclusion
In this study the response to MTX was not associated
with RFC and ATIC polymorphisms. The pharmacoge-
nomics related to MTX is probably quite complex. One
probably needs to study all polymorphisms in the
related enzymes and associated pathways to predict
response to MTX.
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